Apomorphine, a dopamine agonist for the treatment of Parkinson’s disease symptoms [51], was found in our Alzheimer’s disease drug discovery pilot screen to be a potent small-molecule compound with significant power in ameliorating both the aggregation and cytotoxicity of the wildtype p-tau [52]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.